A 52-Week Study of BLU-5937 for Chronic Cough
This study tests the effectiveness and safety of a drug called BLU-5937 for adults who suffer from Refractory Chronic Cough (RCC). Refractory means the cough hasn't gone away with other treatments. The study lasts for 52 weeks, but the main focus is on how the drug works after 12 weeks. Participants will receive either BLU-5937 or a placebo, which is a harmless pill with no medicine, to compare results.
- The study lasts for one year, with a key check-in at 12 weeks.
- Participants must attend regular visits and follow study guidelines.
- You must not smoke or have certain medical conditions to participate.
To join, you must have had a chronic cough for at least one year and agree to use effective birth control if you're a woman who can have children. You also cannot join if you have certain health issues like lung disease or have smoked recently. This study helps researchers learn how well BLU-5937 can help people with chronic coughs.